Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Cost of Revenue: 2015-2024

Historic Cost of Revenue for Heron Therapeutics (HRTX) over the last 10 years, with Dec 2024 value amounting to $47.1 million.

  • Heron Therapeutics' Cost of Revenue rose 17.95% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 0.97%. This contributed to the annual value of $47.1 million for FY2024, which is 30.39% down from last year.
  • Latest data reveals that Heron Therapeutics reported Cost of Revenue of $47.1 million as of FY2024, which was down 30.39% from $67.6 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Cost of Revenue registered a high of $87.2 million during FY2021, and its lowest value of $47.1 million during FY2024.
  • Moreover, its 3-year median value for Cost of Revenue was $67.6 million (2023), whereas its average is $65.7 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 36.53% in 2021, then slumped by 30.39% in 2024.
  • Heron Therapeutics' Cost of Revenue (Yearly) stood at $63.9 million in 2020, then soared by 36.53% to $87.2 million in 2021, then decreased by 5.35% to $82.5 million in 2022, then dropped by 18.02% to $67.6 million in 2023, then tumbled by 30.39% to $47.1 million in 2024.